Anti-Obesity Effect of Diphlorethohydroxycarmalol Isolated from Brown Alga Ishige okamurae in High-Fat Diet-Induced Obese Mice

• Published in: Marine drugs 2019-11, Vol.17 (11), p.637
• Main Authors: Ding, Yuling, Wang, Lei, Im, SeungTae, Hwang, Ouibo, Kim, Hyun-Soo, Kang, Min-Cheol, Lee, Seung-Hong
• Format: Article
• Language: English
• Subjects: Acetyl-CoA carboxylase; Adenosine kinase; Adenosine monophosphate; Adipocytes; Adipose tissue; Adipose Tissue - drug effects; adiposity; Administration, Oral; Algae; AMP; AMP-activated protein kinase; animal disease models; Animals; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - isolation & purification; Anti-Obesity Agents - pharmacology; anti-obesity effect; Aspartate transaminase; Bioactive compounds; blood serum; Body weight; body weight changes; Body weight gain; Chemical compounds; Cholesterol; Density; Diabetes; Diet; Diet, High-Fat; diphlorethohydroxycarmalol (dphc); Disease Models, Animal; Dose-Response Relationship, Drug; Enzymes; epididymis; Ethanol; Fatty acids; Heterocyclic Compounds, 3-Ring - administration & dosage; Heterocyclic Compounds, 3-Ring - isolation & purification; Heterocyclic Compounds, 3-Ring - pharmacology; high density lipoprotein cholesterol; High fat diet; high-fat diet mice; In vivo methods and tests; Insulin resistance; Ishige okamurae; Kinases; Leptin; Lipid metabolism; Lipid Metabolism - drug effects; Lipids; Lipogenesis; Lipogenesis - drug effects; Lipoproteins; Liver; low density lipoprotein cholesterol; Male; Metabolism; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Obesity - drug therapy; Obesity - physiopathology; obesity-related diseases; Oral administration; Overweight; Oxidation; peroxisome proliferator-activated receptor gamma; Phaeophyceae - metabolism; Pharmacology; Phosphorylation; Protein kinase; Proteins; Public health; Serum; Sterol regulatory element-binding protein; Transaminase; triacylglycerols; Triglycerides; Weight Gain - drug effects
• ISSN: 1660-3397; 1660-3397
• DOI: 10.3390/md17110637

Diphlorethohydroxycarmalol (DPHC) is one of the most abundant bioactive compounds in . The previous study suggested that DPHC possesses strong in vitro anti-obesity activity in 3T3-L1 cells. However, the in vivo anti-obesity effect of DPHC has not been determined. The current study explored the effect of DPHC on high-fat diet (HFD)-induced obesity in C57BL/6J mice. The results indicated that oral administration of DPHC (25 and 50 mg/kg/day for six weeks) significantly and dose-dependently reduced HFD-induced adiposity and body weight gain. DPHC not only decreased the levels of triglyceride, low-density lipoprotein cholesterol, leptin, and aspartate transaminase but also increased the level of high-density lipoprotein cholesterol in the serum of HFD mice. In addition, DPHC significantly reduced hepatic lipid accumulation by reduction of expression levels of the critical enzymes for lipogenesis including SREBP-1c, FABP4, and FAS. Furthermore, DPHC remarkably reduced the adipocyte size, as well as decreased the expression levels of key adipogenic-specific proteins and lipogenic enzymes including PPARγ, C/EBPα, SREBP-1c, FABP4, and FAS, which regulate the lipid metabolism in the epididymal adipose tissue (EAT). Further studies demonstrated that DPHC significantly stimulated the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) in both liver and EAT. These results demonstrated that DPHC effectively prevented HFD-induced obesity and suggested that DPHC could be used as a potential therapeutic agent for attenuating obesity and obesity-related diseases.